Biogen to pay $1.25B to de-risk a Tecfidera patent battle, and Forward Pharma’s shares rocket up
Biogen will pay Forward Pharma $1.25 billion in cash to help satisfy the Danish biotech’s claims that its flagship multiple sclerosis drug Tecfidera interfered with its patents.
The pricey settlement comes in exchange for a license agreement on the technology used in the 480 mg daily dose, which was at the center of the IP dispute. And if Forward wins their interference case before the Patent Trial and Appeal Board, Biogen has agreed to pay a royalty on sales.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.